HP-β-CD
Based on 32 publication(s) in Google Scholar
HP-β-CD ((2-Hydroxypropyl)-β-cyclodextrin) is a widely used drug delivery vehicle to improve the stability and bioavailability.
For research use only. We do not sell to patients.
- Purity: 99.74%
- CAS No.: 128446-35-5
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) HP-β-CD
More- Nature. 2025 Sep;645(8080):475-483. [Abstract]
- Cancer Res. 2024 Sep 16;84(18):3004-3022. [Abstract]
- Nat Commun. 2022 May 31;13(1):3022. [Abstract]
- Acta Pharm Sin B. 2026 Feb 10.
- Sci Adv. 2025 Jul 11;11(28):eadv0079. [Abstract]
- Nano Today. 2024 Feb:54:102058. [Abstract]
- Cell Rep Med. 2023 Apr 18;4(4):101015. [Abstract]
- J Immunother Cancer. 2023 Feb;11(2):e005837. [Abstract]
- J Neuroinflammation. 2023 Dec 7;20(1):293. [Abstract]
- BMC Med. 2024 Feb 5;22(1):57. [Abstract]
- Cell Rep. 2018 Dec 11;25(11):2972-2980.e5. [Abstract]
- EMBO Rep. 2024 Oct;25(10):4515-4541. [Abstract]
- JCI Insight. 2024 Nov 5:e183889. [Abstract]
- Cancer Cell Int. 2021 Apr 15;21(1):216. [Abstract]
- Cancer Immunol Immunother. 2024 Feb 17;73(3):57. [Abstract]
- Int J Mol Sci. 2024 Nov 4;25(21):11827. [Abstract]
- PLoS Pathog. 2023 Aug 18;19(8):e1011581. [Abstract]
- Front Cell Infect Microbiol. 2021 Jul 23:11:705087. [Abstract]
- Int Immunopharmacol. 2021 Jul:96:107643. [Abstract]
- Neuropharmacology. 2026 May 1:288:110833. [Abstract]
- J Inflamm (Lond). 2025 Aug 12;22(1):33. [Abstract]
- Neurochem Res. 2025 Aug 25;50(5):277. [Abstract]
- Parasit Vectors. 2025 Jul 4;18(1):259. [Abstract]
- Adv Ophthalmol Pract Res. 2026 Jan 14.
- Am J Physiol Endocrinol Metab. 2025 Oct 24. [Abstract]
- Curr Eye Res. 2022 Dec;47(12):1578-1589. [Abstract]
- Transpl Immunol. 2025 Jan 30:102177. [Abstract]
- bioRxiv. 2026 Feb 2:2026.01.30.702866. [Abstract]
- bioRxiv. 2025 Oct 15:2025.10.14.682312. [Abstract]
- bioRxiv. 2025 Sep 23:2025.09.22.677923. [Abstract]
- University of Sao Paulo. 2025 Jul 17.
- Patent. US20200268864A1.
Biological Activity
Cell treatment with HP-β-CD results in the activation of the transcription factor EB, a master regulator of lysosomal function and autophagy, and in enhancement of the cellular autophagic clearance capacity[1]. HP-β-CD treatment reduces intracellular cholesterol resulting in significant leukemic cell growth inhibition through G2/M cell-cycle arrest and apoptosis. The IC50 values for HP-β-CD after 72 hours exposure are in the range of 3.86-10.09 mM. HP-β-CD also shows anticancer effects against CML cells expressing a T315I BCR-ABL mutation (that confers resistance to most ABL tyrosine kinase inhibitors), and hypoxia-adapted CML cells that have characteristics of leukemic stem cells. In addition, colony forming ability of human primary AML and CML cells is inhibited by HP-β-CD[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 128446-35-5
-
Appearance Solid
-
Color White to off-white
-
SMILES
CO[C@@H]1[C@H](O[R])[C@@H](O)[C@H](C)[C@@H](CO[R])O1.[C;D2]CC(O)C.[R].[7].[R=H or]
-
Synonyms
(2-Hydroxypropyl)-β-cyclodextrin
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (32)
-
Journal Impact Factor
-
Most Recent
-
Nature
2025 Sep;645(8080):475-483. PMID: 40739348 -
Cancer Res
Asparagine Dependency is a Targetable Metabolic Vulnerability in TP53-Altered Castration-Resistant Prostate Cancer. [Abstract]2024 Sep 16;84(18):3004-3022. PMID: 38959335 -
Nat Commun
STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. [Abstract]2022 May 31;13(1):3022. PMID: 35641483 -
-
Sci Adv
NLRP3 inflammasome-driven hemophagocytic lymphohistiocytosis occurs independent of IL-1β and IL-18 and is targetable by BET inhibitors. [Abstract]2025 Jul 11;11(28):eadv0079. PMID: 40632844 -
Nano Today
Reprogramming the pancreatic cancer stroma and immune landscape by a silicasome nanocarrier delivering nintedanib, a protein tyrosine kinase inhibitor. [Abstract]2024 Feb:54:102058. PMID: 38681872 -
Cell Rep Med
A kinome-wide CRISPR screen identifies CK1α as a target to overcome enzalutamide resistance of prostate cancer. [Abstract]2023 Apr 18;4(4):101015. PMID: 37075701 -
J Immunother Cancer
2023 Feb;11(2):e005837. PMID: 36805920 -
J Neuroinflammation
The hypothalamic steroidogenic pathway mediates susceptibility to inflammation-evoked depression in female mice. [Abstract]2023 Dec 7;20(1):293. PMID: 38062440 -
BMC Med
Epigenetic drug screening for trophoblast syncytialization reveals a novel role for MLL1 in regulating fetoplacental growth. [Abstract]2024 Feb 5;22(1):57. PMID: 38317232 -
Cell Rep
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. [Abstract]2018 Dec 11;25(11):2972-2980.e5. PMID: 30540933 -
EMBO Rep
Glutaminolysis provides nucleotides and amino acids to regulate osteoclast differentiation in mice. [Abstract]2024 Oct;25(10):4515-4541. PMID: 39271775 -
JCI Insight
BPDCN MYB fusions regulate cell cycle genes, impair differentiation, and induce myeloid-dendritic cell leukemia. [Abstract]2024 Nov 5:e183889. PMID: 39499902 -
Cancer Cell Int
Trichostatin A downregulates bromodomain and extra-terminal proteins to suppress osimertinib resistant non-small cell lung carcinoma. [Abstract]2021 Apr 15;21(1):216. PMID: 33858423 -
Cancer Immunol Immunother
Targeting myeloperoxidase limits myeloid cell immunosuppression enhancing immune checkpoint therapy for pancreatic cancer. [Abstract]2024 Feb 17;73(3):57. PMID: 38367056 -
Int J Mol Sci
Development and Evaluation of ABI-171, a New Fluoro-Catechin Derivative, for the Treatment of Idiopathic Pulmonary Fibrosis. [Abstract]2024 Nov 4;25(21):11827. PMID: 39519378 -
PLoS Pathog
Targeting FoxO proteins induces lytic reactivation of KSHV for treating herpesviral primary effusion lymphoma. [Abstract]2023 Aug 18;19(8):e1011581. PMID: 37594999 -
Front Cell Infect Microbiol
Pharmacological Targeting of BMP6-SMAD Mediated Hepcidin Expression Does Not Improve the Outcome of Systemic Infections With Intra-Or Extracellular Gram-Negative Bacteria in Mice. [Abstract]2021 Jul 23:11:705087. PMID: 34368018 -
Int Immunopharmacol
25-Hydroxycholesterol mitigates hepatic ischemia reperfusion injury via mediating mitophagy. [Abstract]2021 Jul:96:107643. PMID: 33878616 -
Neuropharmacology
Assessing the utility of the neurosteroid zuranolone to modify alcohol-related behaviours. [Abstract]2026 May 1:288:110833. PMID: 41520874 -
J Inflamm (Lond)
Hydroxychloroquine reduces metastatic tumor burden in pancreatic adenocarcinoma through myeloperoxidase inhibition. [Abstract]2025 Aug 12;22(1):33. PMID: 40797324 -
Neurochem Res
Alamandine Rescues Cognitive Impairment and Ameliorates Alzheimer's Disease-Like Neuropathology in APP/PS1 Mice. [Abstract]2025 Aug 25;50(5):277. PMID: 40853487 -
Parasit Vectors
Comparative analysis of Microtus fortis and murine hosts reveals a correlation between BRD4 and hepatic inflammation during Schistosoma japonicum infection. [Abstract]2025 Jul 4;18(1):259. PMID: 40616163 -
-
Am J Physiol Endocrinol Metab
Control of Hepatic Gluconeogenesis in Mice Fed a High Protein Diet: A Transcriptional Shift from CREB to FoxO1. [Abstract]2025 Oct 24. PMID: 41134648 -
Curr Eye Res
Effect of Nintedanib Nanothermoreversible Hydrogel on Neovascularization in an Ocular Alkali Burn Rat Model. [Abstract]2022 Dec;47(12):1578-1589. PMID: 36259508 -
Transpl Immunol
Hsp90 and HIF-1α regulate mitophagy by promoting BNIP3 expression in renal ischemia-reperfusion injury. [Abstract]2025 Jan 30:102177. PMID: 39892761 -
bioRxiv
2026 Feb 2:2026.01.30.702866. PMID: 41676495 -
bioRxiv
IRG1/itaconate/NRF2/GSH axis in tumor-associated macrophages drives therapy resistance and immune evasion in BRCA1-deficient breast cancer. [Abstract]2025 Oct 15:2025.10.14.682312. PMID: 41279612 -
bioRxiv
2025 Sep 23:2025.09.22.677923. PMID: 41040222 -
-
Solvent & Solubility
DMSO : 50 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 50 mg/mL (Need ultrasonic)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL; Clear solution; Need ultrasonic and warming and heat to 60°C
Add each solvent one by one: Saline
Solubility: 200 mg/mL; Clear solution; Need ultrasonic
Protocol
Cells are incubated with HP-β-CD at various concentrations (5, 7.5, 10, 15, 20 mM) for 72 hours. Cell viability is assessed using a trypan blue dye exclusion method and cell proliferation is evaluated using a modified methyl-thiazol-diphenyl- tetrazolium (MTT) assay[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice: Mice are intraperitoneally injected with 200 μL vehicle (saline) or (2-Hydroxypropyl)-β-cyclodextrin (50 or 150 mM) for 20 consecutive days 3 days after transplantation, and survival is monitored daily. Leukemic cell engraftment is confirmed by detection of GFP-positive cells in the recipient’s BM using flow cytometry[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Song W, et al. 2-Hydroxypropyl-β-cyclodextrin promotes transcription factor EB-mediated activation of autophagy: implications for therapy. J Biol Chem. 2014 Apr 4;289(14):10211-22. [Content Brief]
[2]. Yokoo M, et al. 2-Hydroxypropyl-β-Cyclodextrin Acts as a Novel Anticancer Agent. PLoS One. 2015 Nov 4;10(11):e0141946. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz